<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00961025</url>
  </required_header>
  <id_info>
    <org_study_id>DA1229_DM_I</org_study_id>
    <nct_id>NCT00961025</nct_id>
  </id_info>
  <brief_title>A Study to Characterize the Pharmacokinetics/Pharmacodynamics and Effect of Food of DA-1229 in Healthy Male Subjects</brief_title>
  <official_title>A Dose Block-randomized, Double-blind, Placebo-controlled, Single/Multiple Dosing, Dose Escalation Clinical Phase 1 Study to Investigate the Safety, Tolerance, and Pharmacokinetics/Pharmacodynamics of DA-1229 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <brief_summary>
    <textblock>
      This is a dose block-randomized, double-blind, placebo-controlled, single/multiple dosing,
      dose-escalation study. The study is designed to describe the relationship between multiple
      doses and pharmacokinetic/pharmacodynamic parameters of DA-1229 as well as safety profile.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">March 2010</completion_date>
  <primary_completion_date type="Anticipated">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To characterize the pharmacokinetic/pharmacodynamic of DA-1229 in healthy male subjects</measure>
    <time_frame>Multiple blood and urine samples will be collected for 120 hours after dosing of DA-1229</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerance of DA-1229</measure>
    <time_frame>up to 10 days (single dose study), 17 days (single dose study for food effect), 20 days (multiple dose study)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Diabetes Mellitis Type 2</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DA-1229</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DA-1229</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-1229</intervention_name>
    <description>single dose study : DA-1229 1.25,2.5,5,10,20,40,60mg
multiple dose study : DA-1229 5,10,20,40mg</description>
    <arm_group_label>DA-1229</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20-45 years healthy male subjects

          -  Body weight :50-90kg, BMI between 18.5-25

          -  Blood glucose level of 70-110mg/dL on the FPG test

        Exclusion Criteria:

          -  have a family history of diabetes

          -  Serum AST(SGOT), ALT(SGPT)&gt;1.25 times upper limit of normal

          -  Creatinine clearance rate&lt;80mL/min

          -  show SBP =&lt;100mmHg or &gt;=150mmHg, or DBP=&lt;65mmHg or &gt;=95mmHg, or tachycardia
             (PR&gt;=100times/min)

          -  have a history of drug abuse or show positive for drug abuse or cotinine at urine
             screening

          -  smokers

          -  can not digest high-fat or high-calorie food(applicable only for the 10mg dose group
             subjects
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kyung-Sang Yu, M.D., Ph.d., M.B.A.</last_name>
    <phone>+82-2-2072-1920</phone>
    <email>ksyu@snuh.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Trials Center, Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Chongo-Gu, Yon-Gon Dong</state>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyung-Sang Yu, M.D., Ph.D., M.B.A</last_name>
      <phone>+82-2-2072-1920</phone>
      <email>ksyu@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Kyung-Sang Yu, M.D.,Ph.D.,M.B.A.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>In-Jin Jang, M.D.,Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2009</study_first_submitted>
  <study_first_submitted_qc>August 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2009</study_first_posted>
  <last_update_submitted>August 20, 2009</last_update_submitted>
  <last_update_submitted_qc>August 20, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2009</last_update_posted>
  <responsible_party>
    <name_title>KEUMJAE KO / Assistant Manager</name_title>
    <organization>Clinical Development Team 1</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

